This page includes links to articles highlighting the top hematologic cancer research published on Cancer Therapy Advisor in ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Research presented at SABCS 2024 highlighted efforts to expand treatment options for early breast cancer as well as ...

Research presented at ASH 2024 could change the treatment of patients with newly diagnosed and relapsed or refractory MM, ...

Research presented at ASH 2024 has shed new light on treatment strategies for mantle cell lymphoma and follicular lymphoma.

The FDA has approved Ensacove (ensartinib) to treat patients with ALK+ advanced NSCLC who have not previously received an ALK inhibitor.

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.

There is no indication that Luigi Mangione, the man charged with killing UnitedHealthcare CEO Brian Thompson, was ever a client of UnitedHealthcare, according to authorities.

President-elect Donald Trump is calling for an end to daylight saving time, a practice he described as inconvenient and costly.

The FDA has approved Ryoncil (remestemcel-L-rknd) for the treatment of steroid-refractory acute GVHD in pediatric patients age 2 months and older.

In a phase 3 trial, ASCT did not improve survival outcomes in patients with MCL who had an MRD-negative CR after induction.

The risk of melanoma-related death is greater for patients with primary tumors that are 0.8-1.0 mm thick than for patients with thinner tumors, data suggest.